receptor agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-23. Anything still debated is marked as such rather than presented as settled.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | visual inspection of solid |
| Solubility | Freely soluble in water, pH dependent | buffer choice affects clarity |
| Typical storage | -20 °C, desiccated, protected from light | solution form kept at 2-8 °C |
| Primary purity method | RP-HPLC with UV detection, 214-220 nm | reported as area percent |
| Identity confirmation | LC-ESI-MS, approximately 4114 Da | compared with theoretical mass |
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
For services to Further Education and Skills Michael Davidson. Volunteer and Trustee, Royal Ulster Constabulary George Cross Foundation. For Voluntary Service. Janet Ann Davies. Councillor, Denbighshire County Council. For services to Local Government, to the NHS and to the community in Rhuddlan, Denbighshire. Jean Carol Davies. Chair and Coach, Saints Netball Club, Truro. For services to Netball and to the community in Cornwall. Dr Robert Havard Davies. Doctor, Neuro-Development Team, Betsi Cadwaladr University Health Board. For services to the NHS. Francisco Domingo Davila Davila. For services to the community in Wymondham, Norfolk. Brendan William Davis. Head of Operations, Government Car Service. For services to Government and Major Events. Rachel Frances Davis. For services to the community in Cranford, Northamptonshire. Audrey Dempsey. Founder, Glasgow's No1 Baby and Family Support Service. For services to Families and Vulnerable People in Glasgow. Janet Mary Dicks. For services to the community in Hadleigh, Suffolk. Ann Doreen May Doody. For services to the community in Ilfracombe, Devon. Trevor Samuel John Douglas. General Manager, Belfast Cathedral. For services to Peacebuilding and to the community in Northern Ireland. Lee William Doyle. Chief Executive Officer, Brentford FC Community Sports Trust. For services to Sport and to the community in Brentford, London Borough of Hounslow. Janet Shirley Dyer. Catering Manager, National Fire Service College. For services to the community in Moreton-in-Marsh, Gloucestershire. Patricia Carol Earl.
== Litigation == CLIA itself has not been the subject of much litigation. Federal district courts have held that the CLIA did not create a private cause of action for individuals to sue laboratories that do not comply with its provisions.
Trimeperidine, sold under the brand name Promedol, is an opioid analgesic that is an analogue of prodine. It was developed in the early 1950s in the Soviet Union during research into the related drug pethidine. Trimeperidine has four structural isomers, of which two are active, the γ isomer trimeperidine, and the β isomer isopromedol. It is around half the potency of morphine as an analgesic, and has been widely used for the treatment of pain. Trimeperidine produces similar effects to other opioids, such as analgesia and sedation, along with side effects such as nausea, itching, vomiting, and respiratory depression, which may be harmful or fatal. Trimeperidine is in Schedule I of the Controlled Substances Act 1970 of the United States as a Narcotic with ACSCN 9646 with an annual aggregate manufacturing quota of 2 grams as of 2014. The free base conversion ratio for salts includes 0.883 for the hydrochloride. Trimeperidine increases the activity of the reticular activating system in the brain. It is listed under the Single Convention for the Control of Narcotic Substances 1961 and is controlled in most countries in the same fashion, as is morphine or heroin. Promedol is included into the standard medication kit, which is carried on the battlefield by every Russian military personnel, as a pain-killer in case wounding.
In February 2020, the biosimilar Amsparity was approved for use in the European Union. In June 2020, the biosimilar Idacio was approved for use in Australia. In July 2020, adalimumab-fkjp (Hulio) was approved for use in the United States. In August 2020, the biosimilar Cadalimab was launched in India by Cadila Pharmaceuticals. In October 2020, Idacio was approved for medical use in Canada. In November 2020, Amgevita, Hulio, and Hyrimoz were approved for medical use in Canada. In February 2021, Yuflyma was approved for medical use in the European Union. In January 2021, Abrilada was approved for medical use in Canada. In November 2021, the biosimilars Libmyris and Hukyndra were approved for medical use in the European Union. In December 2021, adalimumab-aqvh (Yusimry) was approved for medical use in the United States. In December 2021, Yuflyma was approved for medical use in Canada. In January 2022, Simlandi was approved for medical use in Canada. In December 2022, Adalimumab-aacf (Idacio) was approved for medical use in the United States. In January 2023, the CHMP recommended that the high-concentration 100mg/ml Hyrimoz biosimilar be granted a pan-European marketing authorization for all indications covered by the reference medicine, including Crohn's disease, plaque psoriasis, ulcerative colitis, rheumatoid arthritis and uveitis. In January 2023, Simlandi was approved for medical use in Saudi Arabia. In May 2023, Adalimumab-aaty (Yuflyma) was approved for medical use in the United States.
=== Policy on Scouting America === In November 2025, Hegseth in a draft memo proposed eliminating the promotion for Eagle Scouts who join the Army and other services due to the lack of "masculine values" and "promoting gender confusion." He also threatened to cut all support from the Department of Defense to Scouting America. The proposal in the draft memo would eliminate support to the National Jamboree as well as ban military bases from hosting or sponsoring scout units. He claimed that the organization was attacking "boy-friendly" spaces by allowing girls to join the organization in 2018. Military families and retired military have criticized the possible actions by Hegseth, stating it will harm military dependent children who depend on the organization as a stabilizing force. Other critics stated that this proposal would harm the military, as 20 percent of military academy students are former scouts and a number of scouts go directly into the military due to the partnership. Navy Secretary John Phelan wrote a memo of his own, stating, "Passive support to Scouting America through access to military installations and educational opportunities aboard said installations serve as a crucial recruiting and community engagement tool for the [Navy]". On February 27, 2026, Scouting America announced that they would immediately drop the Citizenship in the Society merit badge, will create a military service merit badge and waive registration fees for dependent children of active duty military, National Guard and reserve families.
Sources: en.wikipedia.org
== Taxonomy and distribution == Within the world of taxonomy, the stable 'Classical System' of Michaelsen (1900) and Stephenson (1930) was gradually eroded by the controversy over how to classify earthworms, such that Fender and McKey-Fender (1990) went so far as to say, "The family-level classification of the megascolecid earthworms is in chaos." Over the years, many scientists have developed their own classification systems for earthworms, which led to confusion, and these systems have been and still continue to be revised and updated. The classification system used here which was developed by Blakemore (2000), is a modern reversion to the Classical System that is historically proven and widely accepted. Categorization of a megadrile earthworm into one of its taxonomic families under suborders Lumbricina and Moniligastrida is based on such features as the makeup of the clitellum, the location and disposition of the sex features (pores, prostatic glands, etc.), number of gizzards, and body shape. Currently, over than 6,000 species of terrestrial earthworms are named, as provided in a species name database, but the number of synonyms is unknown. The families, with their known distributions or origins:
Denaturation stage. DNA is denatured at a high temperature – usually 94 °C (201 °F). Intermediate annealing stage. Set an intermediate annealing temperature that allows hybridization of mutant and wildtype allele DNA to one another. Because the mutant allele DNA forms the minority of DNA in the mixture they will be more likely to form mismatch heteroduplex DNA with the wildtype DNA. Melting stage. These heteroduplexes will more readily melt at lower temperatures. Hence they are selectively denatured at the Tc. Primer annealing stage. The homo-duplex DNA will preferentially remain double stranded and not be available for primer annealing. Extension stage. The DNA polymerase will extend complementary to the template DNA. Since the heteroduplex DNA is used as template, a larger proportion of minor variant DNA will be amplified and be available for subsequent rounds of PCR. There are two forms of COLD-PCR that have been developed to date. Full COLD-PCR and fast COLD-PCR.
On July 22, 2025, the United States informed of its decision to withdraw from UNESCO, effective December 31, 2026. In a presidential memorandum issued on January 7, 2026, Donald Trump directed to start the process of withdrawal of the US from the 66 organizations, agencies and commissions of the United Nations, including UN Framework Convention on Climate Change (UNFCCC), calling them "contrary to the interests of the United States".
=== Myopathies === Inflammatory myopathies are caused by the immune system inappropriately attacking components of muscle, leading to signs of muscle inflammation. They may occur in conjunction with other immune disorders, such as systemic sclerosis, and include dermatomyositis, polymyositis, and inclusion body myositis.
Sources: en.wikipedia.org
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the usual choice, with results reported as area percent. Complementary methods such as size-exclusion chromatography and mass spectrometry are needed because a single separation cannot resolve every impurity class. Purity figures are therefore method dependent and should always be read alongside the technique used.
Oxidation mainly affects methionine residues and is promoted by dissolved oxygen, trace transition metals, and prolonged exposure to light. Buffer choice and the presence of antioxidants in a formulation can alter the rate appreciably. Because the products differ in mass by only a few units, mass spectrometry is often required to detect them.
Published data on long-term ambient stability are limited, so the question remains open rather than settled. Short excursions during transport are common in practice, and many suppliers use insulated packaging with cold packs. Where stability data are absent, cold-chain handling with temperature logging is the safer approach.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.